INTERCEPT PHARMACEUTICALS IN's ticker is and the CUSIP is 45845P908. A total of 6 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q2 2022. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $3,791,430 | +494.1% | 204,500 | +254.4% | 0.00% | – |
Q2 2023 | $638,162 | -54.3% | 57,700 | -44.5% | 0.00% | -100.0% |
Q1 2023 | $1,396,720 | -53.0% | 104,000 | -56.7% | 0.00% | 0.0% |
Q4 2022 | $2,970,037 | -45.4% | 240,100 | -38.4% | 0.00% | -50.0% |
Q3 2022 | $5,438,000 | +139.8% | 389,800 | +137.4% | 0.00% | +100.0% |
Q2 2022 | $2,268,000 | – | 164,200 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
SABBY MANAGEMENT, LLC | 55 | $1,302,000 | 0.05% |
Citadel Advisors | 29,500 | $6,982,000 | 0.01% |
PEAK6 Group LLC | 2,500 | $592,000 | 0.01% |
GROUP ONE TRADING, L.P. | 500 | $118,000 | 0.00% |